Two late-stage clinical trials published on November 8, 2026, in The New England Journal of Medicine show that the investigational triple-agonist drug retatrutide significantly reduces knee osteoarthritis pain and physical function scores while driving substantial weight loss in adults with obesity.
Trials Test Retatrutide for Knee Pain
The international trials, named TRIUMPH-4 and TRIUMPH-1-OA, evaluated adults aged 18 or older with chronic knee pain, radiographic evidence of knee osteoarthritis, and a body mass index of at least 27, according to 2 Minute Medicine. Participants received once-weekly subcutaneous injections of retatrutide or a placebo alongside lifestyle counseling, with acetaminophen permitted as a rescue medication, as reported by Medscape.
In the TRIUMPH-4 trial, 445 participants received either 9 mg or 12 mg of retatrutide or a placebo for 68 weeks. Those taking 9 mg achieved a mean weight reduction of 26.4%, while the 12 mg group reached 28.7%, compared with a 2.1% reduction in the placebo arm.
“We saw very exciting amounts of pain reduction and function improvement over time,” said Patience H. Kolasinski, an adjunct professor of rheumatology at the Perelman School of Medicine at the University of Pennsylvania, to Medscape.
Weight Loss Drives Joint Relief
Researchers theorize that substantial weight loss reduces the mechanical load across the knee joint during everyday activities. Every pound of body weight translates into approximately two to five pounds of force across the knee during walking, stair climbing, or standing up, noted Timothy Gibson, as reported by Medical News TODAY. Retatrutide functions as a triple agonist targeting the GLP-1, GIP, and glucagon receptors. Beyond mechanical unloading, researchers suggest that the medication may indirectly decrease systemic inflammatory signaling by reducing adipose tissue.
“Weight loss alone may not fully explain the findings,” said Şebnem Ünlüişler, chief longevity officer and genetic engineer at the London Regenerative Institute, told Medical News TODAY. Serious adverse events occurred more frequently with retatrutide than with placebo, with gastrointestinal side effects leading to trial discontinuation in some of the active treatment arms and a small portion of placebo arms, according to 2 Minute Medicine.
Common Questions About Retatrutide Trials
How do GLP-1 and triple-agonist drugs affect arthritis?
Data from these phase 3 trials indicate that weight reduction lowers physical stress on weight-bearing joints like the knees. Researchers also study potential reductions in inflammatory signaling from adipose tissue.

What were the primary safety concerns in the trials?
Gastrointestinal events emerged as the most common adverse effects. These side effects resulted in treatment discontinuation for up to 18.2% of participants in the highest retatrutide dose arms.
Are there direct comparisons to existing osteoarthritis treatments?
The published trials did not include direct comparisons against other interventions such as nonsteroidal anti-inflammatory drugs, tramadol, intraarticular glucocorticoids, or other weight management medications like semaglutide.
“We should view medications like retatrutide as potentially valuable tools in managing osteoarthritis, rather than as a cure for the underlying joint disease,” Gibson told Medical News TODAY.
Keep reading